 Home > Active Ingredient News > Study of Nervous System > Translational Psychiatry: Selective serotonin reuptake inhibitors are beneficial for cognition and brain development in patients with 22q11.2 deletion syndrome

Translational Psychiatry: Selective serotonin reuptake inhibitors are beneficial for cognition and brain development in patients with 22q11.2 deletion syndrome

 Last Update: 2021-06-04
 Source: Internet
 Author: User

Tags

serotonin syndrome seizure

serum serotonin

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Cognitive deficits in individuals at risk of psychosis are a major research challenge because current symptomatic treatment strategies are often ineffective.

prevention

Selective serotonin reuptake inhibitors (SSRIs) are candidate drugs that may theoretically exert neuroprotective effects on brain development and slow down cognitive decline.

Valentina Mancini et al.

This retrospective cohort study aimed to determine whether the early treatment of SSRIs in children and adolescents with 22q11DS is related to the long-term effects of cognitive and brain development.

child

Researchers calculated the differences in cognitive and brain development trajectories between different groups and subgroups to explore the potential effects of SSRIs on development.

Loss carriers treated with SSRIs showed lower IQ at baseline, but compared with lack carriers who did not receive any medications, the IQ scores gradually increased over time .

The development trajectory of the overall IQ (FSIQ), verbal intelligence quotient (VIQ), and performance intelligence quotient (PIQ) scores of carriers when receiving or not receiving SSRIs treatment (above), and when receiving or not receiving SSRIs treatment (below) ) Confirm the development trajectory of missing carriers of psychotic symptoms.

Among the carriers of psychotic symptoms who are treated with SSRIs, the IQ test tends to increase over time, but there is no psychotic symptoms who are not treated with SSRIs in the carrier group of psychotic symptoms who are not treated with SSRIs.

The developmental trajectory of the hippocampal subregions (CA4, CA3, CA4) of the missing carrier with or without SSRIs (above) and with or without SSRIs (below).

The absence of carriers receiving or not receiving SSRIs treatment (left picture), the absence of carriers receiving or not receiving SSRIs treatment (right picture), confirmed psychotic symptoms (right picture), the CT development trajectory of the differentiation of brain maturity.

Further explored the correlation between the increase in IQ or brain measurement and factors that may affect the observation results, such as age of onset, dosage, and duration of treatment with SSRIs.

The increase in IQ scores characterizes the developmental trajectory of participants treated with SSRIs, even those with psychotic symptoms.

This is the first cohort study to explore the long-term cognitive and neurological relevance of early treatment of SSRIs in people at high risk of mental illness .

This is the first cohort study to explore the long-term cognitive and neurological relevance of early treatment of SSRIs in people at high risk of mental illness .
The study showed that long-term use long-term use SSRIs SSRIs can improve can improve 22q11.
2 22q11.
2 cognitive deficit carriers, and their brain development have a good effect.
Early and long-term treatment of SSRIs may reduce the cognitive decline associated with 22q11DS psychosis and abnormal brain development.
It lacks the cognitive ability of the carrier and has a good effect on its brain development.
Early and long-term treatment of SSRIs may reduce the cognitive decline associated with 22q11DS psychosis and abnormal brain development.

Original source

Mancini, V.
, Maeder, J.
, Bortolin, K.
et al.
Long-term effects of early treatment with SSRIs on cognition and brain development in individuals with 22q11.
2 deletion syndrome.
Transl Psychiatry 11, 336 (2021).
https ://doi.
org/10.
1038/s41398-021-01456-x

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.